GSMA
9.2.2020 19:05:05 CET | Business Wire | Press release
The GSMA knows that the Coronavirus has created disruption, in particular for exhibitors and attendees from around the world, including the 5-6,000 (5-6%) who have historically attended from China. Our sympathy goes to all those affected. We are grateful for the preventative measures our Chinese exhibitors have put in place, notably ZTE and Huawei. Today, the GSMA is moving ahead as planned and will host MWC Barcelona 24-27 February 2020. While the GSMA confirm some large exhibitors have decided not to come to the show this year with others still contemplating next steps, we remain more than 2,800 exhibitors strong.
In addition to all of the health and safety measures put in place, the Spanish health authorities, Host City Partners, other relevant agencies and the GSMA are collaborating. The GSMA is seeking to reassure attendees and exhibitors that their health and safety are our paramount concern, by the following additional measures being put in place:
- All travellers from the Hubei province will not be permitted access to the event*
- All travellers who have been in China will need to demonstrate proof they have been outside of China 14 days prior to the event (passport stamp, health certificate)
- Temperature screening will be implemented
- Attendees will need to self-certify they have not been in contact with anyone infected.
While further planning is underway, we will continue to monitor the situation and will adapt our plans according to developments and advice we receive. We are contending with a constantly evolving situation, that will require fast adaptability.
Measures being implemented include:
- Increased cleaning and disinfection programme across all high-volume touchpoints, e.g. catering areas, surfaces, handrails, WCs, entrances/exits, public touch-screens, etc. along with the use of correct cleaning/sanitising materials and products
- Increased onsite medical support – doubled over last year
- Awareness campaign via online and onsite info-share and signage
- Availability of sanitising and disinfection materials for public use
- Awareness and training to all staff on standard personal preventative measures, e.g. personal hygiene, frequency of use of sanitising/disinfection products, etc.
- Advice to exhibitors on implementing effective cleaning and disinfection of stands, offices along with guidance on personal hygiene measures and common preventive behaviour
- Public health guidelines and advice communication to Barcelona hotels, public and private transport, restaurants and catering outlets, retail, etc.
- Installing new signage onsite reminding attendees of hygiene recommendations
- Implementing a microphone disinfecting and change protocol for all speakers
- Communicating advice to all attendees to adopt a ‘no-handshake policy’
- A 24-hour telephone Security and Medical service for all attendees, operational from 12th to 29th February 2020. This number appears on the back of badge holders, in the event App and on signage around the venue.
We understand that in a press conference on Friday 7 February Health Minister Alba Vergés explained that the region of Catalonia is not a public health risk zone. The Health Minister stated “The Catalan health system is prepared to detect and treat coronavirus, to give the most appropriate response, and this must be clear to those attending MWC Barcelona,” said Vergés.
In a similar vein, the Secretary of Public Health, Joan Guix, noted that Catalonia is used to continually welcoming thousands of visitors to the region and reiterated his confidence in the regions readiness and responsiveness. Guix outlined the measures that the Public Health Agency of Catalonia had put in place and that the Spanish Ministry of Health was in constant communication with all relevant bodies. These include the Directorate General of Tourism and Hotels, both public and private health centres, the Chinese consulate and with the GSMA.
Finally, the head of the Service of Preventive Medicine and Epidemiology of the Hospital Clínic de Barcelona, Antoni Trilla, emphasised that “we are not in an exceptional situation and our health system is ready”. The press release can be found here: https://govern.cat/salapremsa/notes-premsa/382568/verges-catalonia-is-prepared-to-detect-and-treat-novel-coronavirus
The GSMA strongly urges exhibitors and attendees to implement appropriate guidelines and protocols as suggested by the WHO and other health authorities to contain and mitigate against any further spread of the virus. The health and safety of our exhibitors, attendees and staff are of paramount importance.
Further updates from the GSMA, answers to the most frequently asked questions and an outline of the measures that have been implemented, are on our website and can be found on www.mwcbarcelona.com .
-ENDS-
Notes to Editors
*By event we mean that to cover MWC Barcelona, Four Years From Now (4YFN), xside and YoMo
Up-to-date WHO advice can be found here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance and the most recent press release issued by WHO is here: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) .
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Shanghai and Los Angeles, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200209005026/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
